Citalopram (Celexa, Forest Laboratories, Parke-Davis) has been approved by FDA for treatment of depression. A highly selective serotonin reuptake inhibitor, citalopram is the best-selling antidepressant in 13 countries, including eight in Europe. Citalopram has proven effective in treatment of depression in clinical trials involving 23,000 patients and has been used in some 8 million patients in 64 countries where the drug is already approved. Two, six-month, double-blind, placebo-controlled studies indicated ... Read More

Concomitant administration of imipramine, lithium, and levomepromazine had no effect on Tmax values of citalopram or its metabolites. In contrast, cimetidine caused a statistically significant decrease in the Tmax value of citalopram and an increase in that of DCT. In an evaluation of the effects of psychotropic drugs on serum citalopram concentrations in psychiatric patients, individual neuroleptics (perphenazine, thioridazine, periciazin, chlorpromazine, haloperidol, zuclopenthixol, and levomepromazine) had no effect on serum citalopram ... Read More

Directions for use conveyed in the sponsor's proposed labeling are as follows: Citalopram should be administered at a dose of 20 mg once daily. Clinical trials demonstrating antidepressant effectiveness studied the recommended therapeutic dose range of 20-60 mg/day. Patients not responding to 20 mg may benefit from dose increases, in 20 mg/day increments, up to a maximum of 60 mg/day. Dose changes should occur at intervals of at least one week. Citalopram ... Read More